OXURION (EBR:OXUR) | Finanzwire

Basculer en Français

10795	Companies
233288	Keywords
161885	Articles
124452	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 05/09/2025 at 18:00, 1 year 2 months ago

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Atlas Special Opportunities, LLC converts 4 convertible bonds in Oxurion, resulting in EUR 100,000 capital increase, supporting innovative therapeutics development for vision preservation in elderly. Oxurion shares update post-capital increase

Capital Increase Oxurion Atlas Special Opportunities, LLC Innovative Therapeutics Vision Preservation
BRIEF

published on 04/25/2025 at 18:35, 1 year 3 months ago

Oxurion Stops 2024 Transaction and Continues Negotiations for New Acquisition

Acquisition Negotiations CRO Oxurion Biometrics
PRESS RELEASE

published on 04/25/2025 at 18:30, 1 year 3 months ago

Oxurion announces that the transaction of July 2024 is stopped and confirms continuation of discussions regarding the acquisition project announced in March 2025
Oxurion NV halts acquisition of French CRO, pursues deal with biometrics CRO to expand capabilities in clinical data management. Progress updates to follow

Acquisition CRO Oxurion NV Clinical Data Management Biometrics
BRIEF

published on 04/11/2025 at 20:05, 1 year 3 months ago

Oxurion Publishes its 2024 Annual Report and Convenes its General Meeting

Forward-looking Statements Annual Report 2024 Ophthalmic Therapies Shareholders' Meetings Oxurion NV
PRESS RELEASE

published on 04/11/2025 at 20:05, 1 year 3 months ago

Publication Annual Report - Annual Shareholders' Meeting
Oxurion NV releases its annual report for the financial year 2024 and convenes its Annual Shareholders' Meeting in Leuven, Belgium. Developing ophthalmic therapies for retinal disease

Shareholders' Meeting Annual Report Ophthalmic Therapies Oxurion NV Retinal Disease
BRIEF

published on 04/04/2025 at 14:05, 1 year 3 months ago

Oxurion General Meeting Postponed

General Meeting Biopharmaceuticals Report Ophthalmic Therapies Oxurion
PRESS RELEASE

published on 04/04/2025 at 14:00, 1 year 3 months ago

Postponement Annual Shareholders Meeting
Oxurion NV postponed its Annual Shareholders Meeting to May 13, 2025, due to pending annual accounts. The biopharmaceutical company, focused on ophthalmic therapies, is based in Leuven, Belgium

Biopharmaceutical Annual Shareholders Meeting Postponed Ophthalmic Therapies Oxurion NV
BRIEF

published on 04/02/2025 at 18:05, 1 year 4 months ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Actions Transparency Atlas Special Opportunities Oxurion Biopharmacy
PRESS RELEASE

published on 04/02/2025 at 18:00, 1 year 4 months ago

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV, a biopharmaceutical company, received a transparency notification from Atlas Special Opportunities II, LLC regarding shareholding threshold crossing under Belgian legislation

Transparency Notification Shareholding Threshold Oxurion NV Belgian Legislation Atlas Special Opportunities II LLC
BRIEF

published on 03/27/2025 at 18:05, 1 year 4 months ago

Oxurion receives adjusted transparency notification

Transparency Notification Shareholding Oxurion Atlas Special Opportunities II Brussels Stock Exchange

Accesswire

Published on 08/01/2026 at 01:20, 2 days 11 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 11 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 12 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 2 days 12 hours ago

BioNxt Solutions Announces Option Grants
Published on 07/31/2026 at 23:20, 2 days 13 hours ago

Pentagon I Capital Corp. Announces Conditional Acceptance of Qualifying Transaction with Prospectiva Resources Ltd.

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 12:33, 16 minutes ago

Diginex Announces Secured US$70 Million Funding Commitments and Extension of Long-Stop Date for Proposed Acquisition of Resulticks
Published on 08/03/2026 at 12:33, 17 minutes ago

EQS-Adhoc: Beiersdorf Aktiengesellschaft: Beiersdorf adjusts guidance for the full year 2026 and resolves NIVEA turnaround plan for the next 18 months
Published on 08/03/2026 at 12:23, 26 minutes ago

EQS-Adhoc: elumeo SE has entered into an agreement with a litigation funder and files a lawsuit for damages against Vodafone
Published on 08/03/2026 at 12:00, 49 minutes ago

SGL Carbon and X-energy announce capacity expansion for Nuclear-Grade Graphite
Published on 08/03/2026 at 11:11, 1 hour 38 minutes ago

Aroundtown SA: Release of a capital market information

Les Echos

Published on 08/03/2026 at 10:58, 1 hour 51 minutes ago

GUILLEMOT CORPORATION| Weekly report share buyback from July 27 to July 31 2026
Published on 08/03/2026 at 08:29, 4 hours 21 minutes ago

Launch of a €225 million tranche of its share buyback programme
Published on 08/03/2026 at 07:00, 5 hours 50 minutes ago

BIOPHYTIS PROVIDES AN UPDATE AND SHARE STRATEGIC DRIVERS SUPPORTING ITS HONG KONG JOINT VENTURE
Published on 07/31/2026 at 21:00, 2 days 15 hours ago

Carrefour completes the sale of its minority stake in CarrefourSA in Turkey to Yeni Mağazacılık A.Ş., operator of the A101 retail chain and controlled by the Aydın Group
Published on 07/31/2026 at 19:27, 2 days 17 hours ago

Share retention commitments (Dutreil Agreement)

View all LES ECHOS COMFI WIRE